KR20230096914A - 항노화 효과를 갖는 폴리펩타이드 및 그의 용도 - Google Patents

항노화 효과를 갖는 폴리펩타이드 및 그의 용도 Download PDF

Info

Publication number
KR20230096914A
KR20230096914A KR1020227005995A KR20227005995A KR20230096914A KR 20230096914 A KR20230096914 A KR 20230096914A KR 1020227005995 A KR1020227005995 A KR 1020227005995A KR 20227005995 A KR20227005995 A KR 20227005995A KR 20230096914 A KR20230096914 A KR 20230096914A
Authority
KR
South Korea
Prior art keywords
composition
skin
amino acid
vitamin
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227005995A
Other languages
English (en)
Korean (ko)
Inventor
옥타비오 프랑코
윌리엄 파리아스 포르토
알레산드라 조나리
카롤리나 레이스 데 올리베이라
에드가 안드레스 오초아
줄리아나 로트 데 카르발호
리어 브레이스
마리아나 보로니
밀리에네스 구이앙
투아니 데 알렌카르 에 실바
Original Assignee
원스킨 인크.
우니앙 브라질레이라 데 에두카상 카톨리쿠 (우베에세)
우니베르시다지 카톨리쿠 데 브라질리아 (우세베)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원스킨 인크., 우니앙 브라질레이라 데 에두카상 카톨리쿠 (우베에세), 우니베르시다지 카톨리쿠 데 브라질리아 (우세베) filed Critical 원스킨 인크.
Publication of KR20230096914A publication Critical patent/KR20230096914A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
KR1020227005995A 2019-07-22 2020-07-22 항노화 효과를 갖는 폴리펩타이드 및 그의 용도 Ceased KR20230096914A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877164P 2019-07-22 2019-07-22
US62/877,164 2019-07-22
PCT/US2020/043033 WO2021016330A2 (en) 2019-07-22 2020-07-22 Polypeptides having anti-senescent effects and uses thereof

Publications (1)

Publication Number Publication Date
KR20230096914A true KR20230096914A (ko) 2023-06-30

Family

ID=74194270

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227005995A Ceased KR20230096914A (ko) 2019-07-22 2020-07-22 항노화 효과를 갖는 폴리펩타이드 및 그의 용도

Country Status (10)

Country Link
US (3) US12268746B2 (enExample)
EP (1) EP4004021B1 (enExample)
JP (2) JP2022541845A (enExample)
KR (1) KR20230096914A (enExample)
CN (1) CN114729015B (enExample)
BR (1) BR112022001229A2 (enExample)
ES (1) ES3049051T3 (enExample)
GB (1) GB2603645B (enExample)
TW (1) TWI862641B (enExample)
WO (1) WO2021016330A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
BR112022001229A2 (pt) 2019-07-22 2022-06-14 Octavio Franco Polipeptídeos tendo efeitos antissenescentes e usos dos mesmos
CN116549325B (zh) * 2022-01-27 2025-07-29 南京大学 一种组合物、其制备方法、制剂及应用
CN114560912B (zh) * 2022-03-28 2023-10-20 碧悦星泽(北京)生物医药科技有限公司 一种具有抗皱功能的多肽及其复合物与应用
CN115404257A (zh) * 2022-06-24 2022-11-29 江西师范大学 一种高通量快速筛选鱼鳞蛋白胶酪氨酸酶抑制肽的方法
CN115105423B (zh) * 2022-07-18 2023-12-22 深圳浦瑞健康科技有限公司 具有抗炎抗敏活性的组合物及其应用
AU2024257036A1 (en) * 2023-04-17 2025-10-16 Hysensbio Co., Ltd Novel use of cpne7 protein-derived peptide

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
WO1995006137A1 (en) 1993-08-27 1995-03-02 Australian Red Cross Society Detection of genes
JP2002539776A (ja) * 1999-03-23 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
AU782102B2 (en) 1999-08-12 2005-07-07 Wisconsin Alumni Research Foundation Identification of genetic markers of biological age and metabolism
US6287778B1 (en) 1999-10-19 2001-09-11 Affymetrix, Inc. Allele detection using primer extension with sequence-coded identity tags
DE10130800B4 (de) 2001-06-22 2005-06-23 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität
WO2003060122A1 (en) 2001-12-21 2003-07-24 Diadexus, Inc. Compositions and methods relating to urinary specific genes and proteins
US20030207280A1 (en) 2002-05-06 2003-11-06 Hsiung Hsiao Determination of physiological conditions defined in traditional chinese medicine
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004108752A1 (en) * 2003-06-11 2004-12-16 Novozymes A/S Antimicrobial polypeptides
US20070259087A1 (en) 2003-06-11 2007-11-08 Novozymes A/S Antimicrobial Peptides
WO2005007129A2 (en) * 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20060107345A1 (en) * 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
CN1569220A (zh) 2004-04-23 2005-01-26 大连帝恩生物工程有限公司 基因重组抗真菌肽在治疗病原真菌感染上的应用
EP2230316A1 (en) 2005-02-01 2010-09-22 AB Advanced Genetic Analysis Corporation Nucleic acid sequencing by performing successive cycles of duplex extension
WO2008143679A2 (en) 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
WO2009097508A2 (en) * 2008-01-30 2009-08-06 Mcanulty, Jonathan Methods and compositions for wound healing
WO2009108713A2 (en) 2008-02-25 2009-09-03 Signum Biosciences, Inc. Topical compositions and methods utilizing peptides containing lipid-modified cysteine-containing peptides
WO2009133098A2 (en) * 2008-04-29 2009-11-05 Dsm Ip Assets B.V. β-LACTAM PRODUCING STRAINS
CA2734521A1 (en) 2008-08-28 2010-03-04 Dermtech International Determining age ranges of skin samples
GB0817121D0 (en) * 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
JP2010115131A (ja) 2008-11-12 2010-05-27 Kao Corp 肌評価方法及び皮膚老化改善剤・皮膚老化予防剤のスクリーニング方法
KR101117195B1 (ko) 2009-07-27 2012-03-07 한국전기연구원 피부 노화도 측정장치 및 측정방법
WO2011026136A1 (en) 2009-08-31 2011-03-03 Life Technologies Corporation Low-volume sequencing system and method of use
WO2012162139A1 (en) 2011-05-20 2012-11-29 The Regents Of The University Of California Method to estimate age of individual based on epigenetic markers in biological sample
US9593363B2 (en) 2012-06-18 2017-03-14 The Procter & Gamble Company Methods and models for assessing anti-aging benefits of agents
US10329614B2 (en) 2013-08-02 2019-06-25 Stc.Unm DNA sequencing and epigenome analysis
CN105765083B (zh) 2013-09-27 2021-05-04 加利福尼亚大学董事会 基于表观遗传学标记物来估计组织和细胞类型的年龄的方法
WO2016118014A2 (en) 2015-01-23 2016-07-28 Erasmus University Medical Center Rotterdam Anti-senescence compounds and uses thereof
AU2016341309A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN119086940A (zh) 2017-04-28 2024-12-06 朋友股份有限公司 变态反应的抗原及其表位
US20190078162A1 (en) 2017-09-14 2019-03-14 OneSkin Technologies, Inc. In vitro methods for skin therapeutic compound discovery using skin age biomarkers
BR112022001229A2 (pt) 2019-07-22 2022-06-14 Octavio Franco Polipeptídeos tendo efeitos antissenescentes e usos dos mesmos

Also Published As

Publication number Publication date
JP2022541845A (ja) 2022-09-27
US20240342290A1 (en) 2024-10-17
GB2603645B (en) 2023-03-01
JP2025123221A (ja) 2025-08-22
US12268747B2 (en) 2025-04-08
EP4004021A2 (en) 2022-06-01
EP4004021B1 (en) 2025-09-03
CN114729015B (zh) 2024-01-12
WO2021016330A3 (en) 2021-03-04
TW202118508A (zh) 2021-05-16
US20250235542A1 (en) 2025-07-24
GB202200959D0 (en) 2022-03-09
TWI862641B (zh) 2024-11-21
GB2603645A (en) 2022-08-10
BR112022001229A2 (pt) 2022-06-14
US20210038729A1 (en) 2021-02-11
US12268746B2 (en) 2025-04-08
CN114729015A (zh) 2022-07-08
WO2021016330A2 (en) 2021-01-28
ES3049051T3 (en) 2025-12-12
EP4004021A4 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
US12268747B2 (en) Polypeptides having anti-senescent effects and uses thereof
US11839679B2 (en) Gamma-diketones for treatment and prevention of aging skin and wrinkles
US12485085B2 (en) PPAR agonist complex and methods of use
WO2017009487A1 (en) Topical compositions
WO2017009489A1 (en) Topical compositions
KR20230065274A (ko) 조직 유래된 매트리킨 조성물 및 이에 대한 방법
WO2017009485A1 (en) Topical compositions
US20240415757A1 (en) Animal-free cosmetic collagens
US20250352608A1 (en) Polypeptides having anti-inflammatory effects and uses thereof
WO2015159854A1 (ja) アンチエイジング用皮膚外用剤
EP3329905A1 (en) Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
WO2018014936A1 (en) Topical compositions
CN116322612A (zh) 用于剥离角质或改善皮肤状态的组合物
US9566222B2 (en) Peptidyl arginine deiminase 1 and/or 3 activator compounds in the epidermis and uses thereof
Somwanshi et al. Cosmetic Science
WO2025122503A1 (en) Banana stem sap compositions and methods of use thereof
KR20170114741A (ko) 피부 상태 개선용 조성물
KR20170114736A (ko) 피부 상태 개선용 조성물
HK1193039A (en) Peptidyl arginine deiminase 1 and/or 3 activator compounds in the epidermis and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000